Moderna Therapeutics, a biotech unicorn valued at more than $7.5 billion, is preparing for an initial public offering that could come as early as this winter, according to people familiar with the process.
The Cambridge, Mass.-based company, which has doggedly stayed private amid a boom of biotech IPOs, has recruited Goldman Sachs, J.P. Morgan, and Morgan Stanley to manage its Wall Street debut, the people said.
About the Author Reprints
